Disease State Education
The scourge of Renal Cell Carcinoma. Unwanted. Unbidden. Often undetected.
For decades, the question has remained the same: How do we stop a disease that continually adapts to survive?
Chemotherapy. Targeted therapy. Immunotherapy. Gene therapy.
What if the next breakthrough doesn't belong to any of them?
What if cancer's greatest vulnerability isn't how it grows but how it feeds itself?
A simple question. A potentially transformative answer.
iCVA
Whether outpatient or inpatient, a heart failure diagnosis can signal the need for urgent action. Any recent hospitalization or urgent incident affects prognosis and treatment.
-
Within 30 days of hospitalization, patients face a 2-fold to 3-fold higher risk of acute HF events.
-
Patients with HF who were hospitalized within 30 days before treatment initiation experienced the greatest benefit from therapy.
Elevated NT-proBNP is a biomarker of cardiac wall stretch in HF.
-
Measurement of natriuretic peptide biomarkers is a Class IA recommendation for diagnosis and prognosis.
-
Elevated NT-proBNP levels may indicate increased cardiac wall stretch or heart failure.
-
A decrease in NT-proBNP of more than 30% has been associated with a reduced risk of cardiovascular death and HF hospitalization.
UNMET NEEDS IN LC-FAOD: CHRONIC SYMPTOMS AND ACUTE EPISODES
LC-FAOD present across a broad spectrum with an unmet clinical need. Despite early detection and management, LC-FAOD mortality rates remain high.
Many patients experience lifestyle limitations, as well as significant morbidities and life-threatening complications, such as chronic symptoms of fatigue, muscle pain, and weakness.
Symptoms arise or are exacerbated during catabolic situations, such as fasting, illness, and endurance exercise. These are chronic and progressive manifestations resulting from prolonged energy deficiency and tissue/vital organs fatty acid accumulation.
Acute episodes often involve rhabdomyolysis, cardiomyopathy, or hypoketotic hypoglycemia and are usually triggered by illness or fasting, but they may occur spontaneously and unpredictably in some LC-FAOD types, with long-lasting implications. These may lead to hospitalization, emergency room visits, emergency treatment interventions, and sudden death
Rare Disease Website
Corporate Manifesto
WE
WILL DELIVER AN UNPRECEDENTED BENEFIT
TIME TO DETECT. CONSIDER. CHOOSE.
FOR THE BEST CHANCE OF SUCCESSFUL TREATMENT
WILL
WAIT FOR NO ONE
BE AN R&D FORCE MULTIPLIER
INSPIRE CHANGE IN CLINICAL PRACTICE
FORGE DYNAMIC COLLABORATIONS
CONQUER
CURRENT LIMITATIONS AND CONSTRAINTS
SO TOMORROW WILL BE PROFOUNDLY BETTER
FOR PATIENT AND PHYSICIANS
WHOSE LIVES ARE AFFECTED BY
CANCER
TRANSFORMING THE FOUNDATIONAL
MOLECULAR INFORMATION TO ENABLE
PRECISION ONCOLOGY
WITH DATA
Device Communication
Continuous glucose monitors (CGMs) promise continuous monitoring and continuous accuracy. Current devices deliver continuous monitoring, alerting users to high and low glucose levels that might be missed by occasional fingersticks.
What about accuracy?
Understanding accuracy requires recognizing that CGMs do not work like fingersticks. Rather than measuring glucose directly from a drop of blood, CGMs measure glucose in interstitial fluid—a thin layer of fluid that surrounds tissue cells just beneath the skin.
Algorithms then convert these measurements into estimated glucose values.
The challenge to accuracy lies in the presence of interfering compounds within the interstitial fluid. Accuracy and interference are closely linked because certain chemicals can prevent current devices from accurately detecting glucose levels.
This is a complex problem.
The FDA currently evaluates the effects of more than 40 potentially interfering substances. Some can cause glucose readings to appear higher than they actually are, while others can cause readings to appear lower. In some cases, the effects of different substances may offset one another. In others, they may compound, resulting in larger increases or decreases in reported glucose levels.
With the potential for interference effects of 50% or more, current devices may be subject to substantial measurement error.
Relaunch of Specialty Brand
The heart is central to life. Every heartbeat sustains it. When the heart stops, life ends.
As you listened to our colleagues share their stories, you probably thought of your own. That's because cardiovascular disease touches nearly every family in America.
Millions of people could stand here and tell a story about themselves, a loved one, a friend, or a colleague. When cardiovascular disease affects someone you care about, empathy and compassion come naturally. So does the desire to help.
Many people feel that calling. Very few are in a position to answer it.
We are.
Every day, we have the opportunity to turn belief into action and make a difference for patients. Through your work, you've already helped address one of the most persistent and devastating health challenges of our time.
You helped physicians become early adopters. You helped them fight for their patients. And you did it before the new label data while navigating some of the toughest access barriers in healthcare.
That's an extraordinary achievement.
Many of you do this instinctively. Now we're going to do it systematically and together.
That's why we created the Adoption Ladder: from Non-Believer, to Beginner, to Believer.
You've moved physicians up that ladder before.
Now let's go even further.
Corporate Website
HOME PAGE
headline
Inspired by Hope.
Focused on Prevention.
Powered by Innovation.
TILE 1
headline
About Novavax
body
We are committed to delivering novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases. We produce vaccine candidates to respond to both known and emerging disease threats efficiently and effectively.
LEADERSHIP QUOTE
headline
We are at the forefront of the fight against infectious disease
body
“Never has our path forward been clearer or the need greater. Our experience developing vaccine candidates for some of the world’s toughest viral threats will use the power of our innovative recombinant nanoparticle vaccine platform, fortified by our Matrix-MTM adjuvant to urgent purpose—to reduce the human toll of vaccine-preventable diseases.”
Stanley Erck
President and Chief Executive Officer
Novavax
TILE 2
eyebrow
Threats continually emerge and evolve
headline
An Agile and Determined Team
body
Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, hardworking, and dedicated, they are driven by a passion to find answers and to solve some of our greatest health challenges.
CTA
Learn About Our Science and Technology
Thought Leadership eMagazine
Healthcare is no longer asking whether data matters. That question has been answered.
Today, healthcare organizations generate and consume unprecedented amounts of information—from electronic health records and claims data to genomics, wearables, remote monitoring, real-world evidence, and AI-powered insights. The challenge is no longer access to data. It is extracting meaningful intelligence from it and turning that intelligence into action.
As artificial intelligence becomes embedded across healthcare, a new question emerges: What will separate leaders from followers?
It won't be who has the most data. Most organizations already have more data than they can effectively use.
It will be who can identify meaningful patterns sooner, make better decisions faster, and translate insights into measurable improvements for patients, providers, and the business.
Healthcare has already made remarkable progress. Predictive analytics help identify patients at risk before adverse events occur. AI is accelerating drug discovery, improving operational efficiency, and supporting clinical decision-making. Commercial teams increasingly use advanced analytics to understand customer needs and optimize engagement.
Yet technology alone is not the answer.
The true opportunity lies at the intersection of human expertise and machine intelligence. Data can reveal patterns. AI can surface possibilities. But people still provide context, judgment, creativity, and accountability.
Perhaps the most important question is not what AI can do for healthcare. It is how healthcare leaders will use AI and analytics to make better decisions, solve more meaningful problems, and create greater value for the people they serve.
Organizations that answer that question successfully will not simply keep pace with change. They will help define what comes next.
Launch of New Sales Force
NSS Vision
-
We’ve been through a lot of change, but what stays constant is our commitment to address unmet needs in CNS
-
To be a transformational “best in industry” Neuroscience Specialist Salesforce driven by performance, employee engagement and seen as a valued partner in the eyes of our customers and patients”
-
We have the opportunity and responsibility to take it to next level
Differentiating Capabilities
-
Utilize deep marketing insights in the psychiatry space
-
Enhance clinical competency and account management skills
-
New KOL strategy & medical partnerships
-
First in class patient programs
Performance Enabled by Culture
-
Capabilities set us up for high performance
-
Our “X factor” comes from living our culture to the fullest
-
NSS will be defined by an engaging and inclusive culture whose focus is constantly on the patient and customer
-
If every business decision and interaction is patient and customer-centric, we will be seen as truly collaborative partners in the eyes of our customers
-
No “light between our shoulders” but we each bring different strengths
Winning by Building on Our Foundation
-
We’re here to maximize the opportunity
-
You’ve joined a team that has great momentum
-
Still an incredible trajectory ahead – by helping appropriate patients
